Volume 13, Issue 4 (Winter 2016)
Sci J Iran Blood Transfus Organ 2016, 13(4): 324-332 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Valikhani A, Rezaei M, Alaei M, Popak B, Amirizade N, Ahmadi M. Study of ASXL1 gene mutation in Chronic Myelogenous Leukemia. Sci J Iran Blood Transfus Organ 2016; 13 (4) :324-332
URL: http://bloodjournal.ir/article-1-977-en.html
URL: http://bloodjournal.ir/article-1-977-en.html
Full-Text [PDF 464 kb]
(1621 Downloads)
| Abstract (HTML) (5509 Views)
Study of ASXL1 gene mutation in Chronic
Myelogenous Leukemia
Valikhani A.1, Rezaei M.S.2, Alaei M.1, Poopak B.3, Amirizade N.1, Ahmadi M.H.1
1Blood Transfusion Research Center, High Institute for research and Education in Transfusion Medicine, Tehran, Iran
2Virology Research Center, National Research Institute of Tuberculosis and Ling Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Hematology, Islamic Azad University, Tehran, Iran
Abstract
Background and Objectives
ASXL1 gene has been recently considered as an important mutant gene in myeloid leukemias including Chronic Myelogenous Leukemia(CML). Mutation in this gene is associated with disease aggressiveness and poor clinical outcome, so its evaluation would guide us to remarkable conclusions in estimating disease prognosis. Considering that there are only a few known prognostic factors for CML and that the study of this gene has never been accomplished in Iranian population, we decided to study this mutation in our CML patients.
Materials and Methods
In this experimental study 66 diagnosed CML patients were evaluated for the presence of ASXL1 mutation. For this reason a portion of exon 12 from ASXL1 gene(site that most mutations take place at), was amplified. This area was further studied by nucleotide sequencing.
Results
Mutations in ASXL1 were detected in 4 CML patients(2 men and 2 women) with mean age of 44 years and SD of 17.85(6%) . Mutations were of two different types including frame shift mutation(c.1394DupG) and deletion(1900-1922del) and both were reported in previous studies. No significant difference was detected in patients with and without mutations, according to sex, age, WBC count, Platelet count and Hemoglobin levels.
Conclusions
ASXL1 gene mutation is considered as a genetic abnormality in CML. According to the presence of this mutation in our patients at the time of diagnosis, it could be regarded as one of the primary genetic distortions in CML.
Key words: ASXL1 protein, human, Mutation , Leukemia
Received: 27 Jul 2015
Accepted: 14 Aug 2016
Correspondence: Alaei M., MD. Pathologist. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052105; Fax: (+9821) 88601599
E-mail: alaeimastaneh@hotmail.com
Full-Text: (3378 Views)
References:
- Gelsi-Boyer V, Trouplin V, Adelaide J, Bonanza J, Carver N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145(6): 788-800.
- Pratcorona M, Abbas S, Sanders M, Koenders J, Kavelaars F, Erpelinck-Verschueren CA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 2012; 97(3): 388-92.
- Aravind L, Iyer LM. The HARE-HTH and associated domains: Novel modules in the coordination of epigenetic DNA and protein modifications. Cell Cycle 2012, 11(1): 119-31.
- Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010, 465(7295): 243-7.
- Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42(8): 722-6.
- Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012; 119(5): 1208-13.
- Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through inhibition of PRC2-mediated gene repression. Cancer Cell 2012; 22(2): 180-93.
- Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2and ASXL1 mutations in myelofibrosis, chronic myelomonocyticleukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25(7): 1200-2.
- Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012; 5: 12.
- Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364(26): 2496-506.
- Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, et al. Combined mutations of asxl1, cbl, flt3, idh1, idh2, jak2, kras, npm1, nras, runx1, tet2 and wt1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010;10: 401.
- Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012; 51(8): 743-55.
- Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, et al. ASXL1 mutation isassociated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010; 151(47): 365-75.
- Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic significance of ASXL1 mutations in patients withmyelodysplastic syndromes. J Clin Oncol 2011; 29(18): 2499-506.
- Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013; 27(1): 82-91.
- Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 2010; 24(6): 1139-45.
- Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 2014; 89(5): 547-56.
- Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, et al. CBL, CBLB, TET2,
ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011; 117(21): e198-206. - Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9 % of cases. Leukemia 2011; 25(3): 557-60.
- Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like mutations. Blood 2011; 116(20): 4086-94.
- Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, et al. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Am J Hematol 2012; 87(7): 659-62.
|
Sci J Iran Blood Transfus Organ 2017; 13(4): 324-332 |
|
Original Article
|
Study of ASXL1 gene mutation in Chronic
Myelogenous Leukemia
Valikhani A.1, Rezaei M.S.2, Alaei M.1, Poopak B.3, Amirizade N.1, Ahmadi M.H.1
1Blood Transfusion Research Center, High Institute for research and Education in Transfusion Medicine, Tehran, Iran
2Virology Research Center, National Research Institute of Tuberculosis and Ling Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Hematology, Islamic Azad University, Tehran, Iran
Abstract
Background and Objectives
ASXL1 gene has been recently considered as an important mutant gene in myeloid leukemias including Chronic Myelogenous Leukemia(CML). Mutation in this gene is associated with disease aggressiveness and poor clinical outcome, so its evaluation would guide us to remarkable conclusions in estimating disease prognosis. Considering that there are only a few known prognostic factors for CML and that the study of this gene has never been accomplished in Iranian population, we decided to study this mutation in our CML patients.
Materials and Methods
In this experimental study 66 diagnosed CML patients were evaluated for the presence of ASXL1 mutation. For this reason a portion of exon 12 from ASXL1 gene(site that most mutations take place at), was amplified. This area was further studied by nucleotide sequencing.
Results
Mutations in ASXL1 were detected in 4 CML patients(2 men and 2 women) with mean age of 44 years and SD of 17.85(6%) . Mutations were of two different types including frame shift mutation(c.1394DupG) and deletion(1900-1922del) and both were reported in previous studies. No significant difference was detected in patients with and without mutations, according to sex, age, WBC count, Platelet count and Hemoglobin levels.
Conclusions
ASXL1 gene mutation is considered as a genetic abnormality in CML. According to the presence of this mutation in our patients at the time of diagnosis, it could be regarded as one of the primary genetic distortions in CML.
Key words: ASXL1 protein, human, Mutation , Leukemia
Received: 27 Jul 2015
Accepted: 14 Aug 2016
Correspondence: Alaei M., MD. Pathologist. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052105; Fax: (+9821) 88601599
E-mail: alaeimastaneh@hotmail.com
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
